Ningshao Xia Selected Research

Drug Therapy (Chemotherapy)

4/2019	Vesicular Antibodies: A Bioactive Multifunctional Combination Platform for Targeted Therapeutic Delivery and Cancer Immunotherapy.
1/2019	Disrupting LILRB4/APOE Interaction by an Efficacious Humanized Antibody Reverses T-cell Suppression and Blocks AML Development.
1/2018	Quantification of HBV core antibodies may help predict HBV reactivation in patients with lymphoma and resolved HBV infection.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Ningshao Xia Research Topics

Disease

72	Infections 12/2022 - 01/2008
22	Hepatitis E 01/2020 - 02/2003
18	Neoplasms (Cancer) 01/2022 - 01/2015
16	Virus Diseases (Viral Diseases) 06/2022 - 01/2014
15	COVID-19 12/2022 - 01/2020
9	Human Influenza (Influenza) 07/2022 - 01/2017
9	Chronic Hepatitis B 01/2022 - 09/2010
9	Hepatitis B 01/2021 - 04/2009
7	Foot and Mouth Disease Hand (Hand, Foot, Mouth Disease) 12/2020 - 11/2013
4	Reinfection 12/2022 - 10/2010
4	Uterine Cervical Neoplasms (Cancer of the Cervix) 01/2021 - 01/2015
4	Hepatitis 05/2014 - 09/2010
3	Herpes Zoster 11/2022 - 07/2010
3	Chickenpox 11/2022 - 07/2010
3	Persistent Infection 08/2021 - 01/2021
3	Hepatocellular Carcinoma (Hepatoma) 01/2021 - 10/2016
3	Communicable Diseases (Infectious Diseases) 01/2021 - 01/2017
3	Papillomavirus Infections 10/2018 - 01/2017
3	Influenza in Birds (Avian Flu) 01/2018 - 05/2009
2	Tuberculosis (Tuberculoses) 04/2022 - 01/2018
2	Pneumonia (Pneumonitis) 01/2022 - 01/2022
2	Acquired Immunodeficiency Syndrome (AIDS) 01/2022 - 11/2018
2	Epstein-Barr Virus Infections 01/2022 - 01/2022
2	Acute Liver Failure (Fulminant Hepatic Failure) 01/2021 - 11/2019
2	Vaccine-Preventable Diseases 01/2020 - 01/2016
2	Leukemia 01/2020 - 01/2019
2	Lymphoma (Lymphomas) 01/2020 - 01/2018
2	Chronic Hepatitis (Chronic Active Hepatitis) 11/2019 - 01/2016
2	Liver Cirrhosis (Hepatic Cirrhosis) 11/2019 - 08/2010
2	Rotavirus Infections 01/2019 - 05/2015
2	Viremia 01/2018 - 10/2010
1	Asymptomatic Infections 12/2022
1	Cytomegalovirus Infections (Inclusion Disease) 03/2022
1	Necrosis 01/2021

Drug/Important Bio-Agent (IBA)

69	VaccinesIBA 11/2022 - 02/2003
21	Antiviral Agents (Antivirals)IBA 12/2021 - 01/2014
20	AntibodiesIBA 12/2022 - 04/2011
20	Monoclonal AntibodiesIBA 01/2022 - 01/2009
19	Proteins (Proteins, Gene)FDA Link 07/2022 - 04/2009
17	Neutralizing AntibodiesIBA 06/2022 - 01/2017
16	AntigensIBA 01/2022 - 03/2010
12	EpitopesIBA 01/2022 - 01/2009
9	RNA (Ribonucleic Acid)IBA 11/2020 - 10/2010
7	Immunoglobulin G (IgG)IBA 03/2022 - 10/2010
7	Immunoglobulin M (IgM)IBA 01/2019 - 11/2009
6	Immune Checkpoint InhibitorsIBA 01/2022 - 01/2016
6	Pharmaceutical PreparationsIBA 01/2021 - 05/2016
6	hecolinIBA 01/2019 - 05/2014
5	Hepatitis B Surface Antigens (HBsAg)FDA Link 01/2022 - 09/2010
5	Hepatitis B e AntigensIBA 01/2021 - 12/2010
5	antineoplaston A10 (A 10)IBA 02/2019 - 05/2009
4	Biomarkers (Surrogate Marker)IBA 04/2022 - 04/2011
4	DNA (Deoxyribonucleic Acid)IBA 03/2022 - 01/2015
4	Indicators and Reagents (Reagents)IBA 01/2022 - 10/2016
4	Immune Sera (Antisera)IBA 12/2021 - 01/2009
4	Broadly Neutralizing AntibodiesIBA 01/2021 - 10/2017
4	Papillomavirus Vaccines (HPV Vaccines)IBA 01/2021 - 01/2015
3	Hemagglutinins (Hemagglutinin)IBA 01/2022 - 10/2017
3	Nucleic AcidsIBA 01/2022 - 01/2015
3	Biological ProductsIBA 01/2021 - 06/2012
3	EnzymesIBA 12/2020 - 03/2013
3	ImmunosorbentsIBA 12/2020 - 03/2013
3	Capsid Proteins (Capsid Protein)IBA 10/2018 - 03/2013
2	Single-Chain AntibodiesIBA 01/2022 - 01/2020
2	Glycoproteins (Glycoprotein)IBA 01/2022 - 01/2022
2	CytokinesIBA 01/2021 - 10/2017
2	NucleoproteinsIBA 01/2021 - 11/2019
2	Circular DNAIBA 01/2021 - 01/2018
2	RNA Polymerase IIIIBA 01/2020 - 08/2017
2	5S Ribosomal RNAIBA 01/2020 - 08/2017
2	Therapeutic UsesIBA 01/2020 - 10/2016
2	Influenza Vaccines (Influenza Vaccine)FDA Link 01/2019 - 10/2017
2	Oseltamivir (Tamiflu)FDA Link 01/2019 - 10/2017
2	Recombinant ProteinsIBA 11/2018 - 02/2003
2	Combined VaccinesIBA 01/2017 - 11/2016
2	Humanized Monoclonal AntibodiesIBA 04/2011 - 07/2010
2	Peptides (Polypeptides)IBA 04/2009 - 01/2008
1	insulin receptor-related receptor (IRR)IBA 12/2022
1	NucleotidesIBA 05/2022
1	Carrier Proteins (Binding Protein)IBA 04/2022
1	Progesterone FDA LinkGeneric 01/2022
1	Alanine (L-Alanine)FDA Link 01/2022
1	NanovaccinesIBA 01/2022
1	Gonadal Steroid Hormones (Sex Hormones)IBA 01/2022
1	N-acetyltalosaminuronic acid (NAT)IBA 01/2022
1	Dexamethasone (Maxidex)FDA LinkGeneric 01/2022
1	Protein Subunits (Protein Subunit)IBA 11/2021
1	Subunit VaccinesIBA 03/2021
1	adefovir dipivoxil (Hepsera)FDA Link 01/2021
1	CarbohydratesIBA 01/2021
1	Acetaminophen (Paracetamol)FDA LinkGeneric 01/2021
1	ChemokinesIBA 01/2021
1	Phosphoprotein Phosphatases (Phosphatases, Protein)IBA 01/2021
1	bamlanivimabIBA 12/2020

Therapy/Procedure

25	Therapeutics 01/2022 - 10/2007
4	Immunotherapy 01/2022 - 04/2019
3	Drug Therapy (Chemotherapy) 04/2019 - 01/2018
2	Intravenous Injections 01/2021 - 12/2019
2	Transplantation 11/2019 - 01/2019
1	Intraperitoneal Injections 12/2021